CEO Seth Lederman said early trends show favorable prescriber uptake and repeat utilization. ・Investors are also watching TNX ...

Tonix Pharmaceuticals Holding Corp. TNXP shares are up during Friday’s premarket session as the company recently reported its ...

Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology ...

Approved To Transfer Listing To Nasdaq Global Select Market. Tonix Pharmaceuticals (NASDAQ: TNXP) announced it has received approval from Nasdaq to transfer the listing of its common stock from the ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced ...

About Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced financial results for the fourth quarter and full ...

TONMYA (cyclobenzaprine HCl sublingual tablets) launched November 17, 2025, for the treatment of fibromyalgia; through February 27, 2026, more than 1,500 healthcare providers have prescribed TONMYA to ...

Data from Stocktwits indicated that retail sentiment remains cautious, with a bearish outlook on SPY and QQQ.

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on PDS Biotechnology, with a price target of $15.00. The company’s shares closed last Monday at $0.64.